D614G Spike Protein
Human-COVID-19-Spike-Protein-IgG-ELISA-Kit |
|||
E28AB0167 | EnoGene | N/A | EUR 666.67 |
Description: N/A |
Human IgG antibody Laboratories manufactures the d614g spike protein reagents distributed by Genprice. The D614G Spike Protein reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other D614G products are available in stock. Specificity: D614G Category: Spike Group: Protein
Anti-Spike-RBD-fully-human-mAb(IgG) |
||
EnoGene | Human,-Human-IgG1.Affinity:(mol)4.15*10-10(Fortebio),-1.07-nM(ELISA).-FACs-Blocking:-0.892-nM- | EUR 416.5 |
Description: Human, Human IgG1.Affinity: (mol) 4.15*10-10 (Fortebio), 1.07 nM (ELISA) . FACs Blocking: 0.892 nM |
Anti-Spike-RBD-fully-human-mAb(IgG) |
||
EnoGene | Human,-Human-IgG1.Affinity:(mol)6.99*10-10(Fortebio),0.38-nM(ELISA).-FACs-Blocking:-0.803-nM- | EUR 416.5 |
Description: Human, Human IgG1.Affinity: (mol) 6.99*10-10 (Fortebio) , 0.38 nM (ELISA) . FACs Blocking: 0.803 nM |
Anti-Spike-RBD-fully-human-mAb(IgG) |
||
EnoGene | Human,-Human-IgG1.-Affinity:(mol)3.1*10-10(Fortebio)0.3-nM(ELISA).-FACs-Blocking:-0.889-nM. | EUR 416.5 |
Description: Human, Human IgG1. Affinity: (mol) 3.1*10-10 (Fortebio) 0.3 nM (ELISA) . FACs Blocking: 0.889 nM. |
Anti-Spike-RBD-fully-human-mAb(IgG) |
||
EnoGene | Humanized-Monoclonal-Antibody,-human-IgG1.-Affinity:0.561-nM(By-ELISA) | EUR 416.5 |
Description: Humanized Monoclonal Antibody, human IgG1. Affinity:0.561 nM (By ELISA) |
Anti-Spike-RBD-fully-human-mAb(IgG) |
||
EnoGene | Humanized-Monoclonal-Antibody.-human-IgG1.-Affinity:0.762-nM(By-ELISA) | EUR 416.5 |
Description: Humanized Monoclonal Antibody. human IgG1. Affinity:0.762 nM (By ELISA) |
JBS True Blue |
||
Jena Bioscience GmbH | 300µl | EUR 13.7 |
JBS True Blue |
||
MiTeGen | 300 µl | EUR 16 |
Description: JBS True Blue |
SARS-CoV-2 Spike Trimer (D614G)-coupled Magnetic Beads |
|||
MBS-K016 | ACROBIOSYSTEMS | 2mg | EUR 4312.1 |
Description: SARS-CoV-2 Spike Trimer (D614G) protein is expressed from human 293 cells (HEK293). It contains AA Val 16 - Pro 1213(Accession # QHD43416.1 (D614G, R683A, R685A)). |
Recombinant SARS-CoV-2 Spike S1(D614G),ECD(Fc Tag) |
|||
PKSV030395-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |
Recombinant SARS-CoV-2 Spike S1(T20N, D614G)(His Tag) |
|||
PKSV030377-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |
Recombinant SARS-CoV-2 Spike S1(L18F, D614G)(His Tag) |
|||
PKSV030399-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |
Recombinant SARS-CoV-2 Spike S1(A222V, D614G)(His Tag) |
|||
PKSV030398-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |
Recombinant SARS-CoV-2 Spike S1(D614G)(His Tag)(Active) |
|||
PKSV030387-500ug | Elabscience Biotech | 500ug | EUR 2280 |
Description: SARS-CoV-2 |
Recombinant SARS-CoV-2 Spike S1(D614G)(His Tag)(Active) |
|||
PKSV030387-50ug | Elabscience Biotech | 50ug | EUR 290 |
Description: SARS-CoV-2 |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
78028-1 | BPS Bioscience | 100 µl | EUR 900 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
78028-2 | BPS Bioscience | 500 µl x 2 | EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial |
|||
E80028 | EpiGentek | 20 µg | EUR 799 |
Recombinant SARS-CoV-2 Spike S1 (HV69-70/Y144 deletion, N501Y, A570D, D614G, P681H) Protein [His] |
|||
DAGC488 | Creative Diagnostics | 100 µg | EUR 1207.5 |
Description: Recombinant |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78035-1 | BPS Bioscience | 100 µl | EUR 860 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78035-2 | BPS Bioscience | 500 µl x 2 | EUR 5145 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Biotinylated SARS-CoV-2 Spike S1 Protein (T19R, G142D, EF156-157del, R158G, L452R, T478K, D614G, P681R), His,Avitag™ |
|||
S1N-C82E5 | ACROBIOSYSTEMS | 25ug | EUR 1872.5 |
Description: Biotinylated SARS-CoV-2 Spike S1, His,Avitag (S1N-C82E5) is expressed from human 293 cells (HEK293). It contains AA Val 16 - Arg 685 (Accession # QHD43416.1). The mutations (T19R, G142D, EF156-157del, R158G, L452R, T478K, D614G, P681R) were identified in the SARS-CoV-2 Delta variant (Pango lineage: B.1.617.2; GISAID clade: GK; Nextstrain clade: 21A/21I/21J). |
Recombinant SARS-CoV-2 Spike S1+S2 ECD (D614G)(His Tag) |
|||
PKSV030392-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |
SARS-CoV-2 (COVID-19) Mu Variant (B.1.621) Spike RBD (R346K, E484K, N501Y, D614G, P681H) Recombinant Protein |
|||
21-830 | ProSci | 0.1 mg | EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biologicalprocesses that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Knownreceptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein ofcoronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Mostnotable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike(S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogenand a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells throughinteraction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits,S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor.S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizingantibodyand T-cell responses, as well as protective immunity. |
Recombinant SARS-CoV-2 Spike S1(W152C, L452R, D614G)(His Tag) |
|||
PKSV030339-100ug | Elabscience Biotech | 100ug | EUR 1105 |
Description: SARS-CoV-2 |